All Phenotypes Slc40a1<tm2Nca> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Meox2^tm1(cre)Sor/Meox2⁺ Slc40a1^tm2Nca/Slc40a1^tm2Nca	involves: 129S4/SvJae * 129S6/SvEvTac	MGI:3771551
cn2	Slc40a1^tm2Nca/Slc40a1^tm2Nca Tg(Vil1-cre)20Syr/0	involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:3771552
cn3	Slc40a1^tm2Nca/Slc40a1^tm2Nca Tg(Vil1-cre/ERT2)23Syr/0	involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:3771553

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

mortality/aging ( J:129846 )

N	• unlike homozygous null mice, mice with conditional deletion in embryonic tissues that retain expression in the extraembryonic visceral endoderm and in the placenta survive past birth

hematopoietic system

anemia ( J:129846 )

• severe iron deficient anemia

abnormal erythrocyte morphology ( J:129846 )

decreased hemoglobin content ( J:129846 )

• at 18 - 22 days of age

decreased mean corpuscular hemoglobin ( J:129846 )

• hypochromic at P10

• reduced in both mature erythrocytes and reticulocytes at 18 - 22 days of age

decreased mean corpuscular volume ( J:129846 )

• at 18 - 22 days of age

anisocytosis ( J:129846 )

• at P10

poikilocytosis ( J:129846 )

• at P10

reticulocytosis ( J:129846 )

• at P10 and at P18 - P22

increased spleen iron level ( J:129846 )

• significant iron accumulation in splenic macrophages at P12

• at P18 - P22 spleen iron are increased 4.4-fold increase compared to controls

growth/size/body

decreased body size ( J:129846 )

• apparent within a few days of birth

• difference from controls becomes more prominent with age

homeostasis/metabolism

increased intestinal iron level ( J:129846 )

• significant iron accumulation in duodenal enterocytes at P12

increased spleen iron level ( J:129846 )

• significant iron accumulation in splenic macrophages at P12

• at P18 - P22 spleen iron are increased 4.4-fold increase compared to controls

abnormal liver iron level ( J:129846 )

• significant iron accumulation in the Kupffer cells and hepatocytes at P12

• at P18 - P22 iron levels in the liver are reduced by 1.7-fold compared to controls

digestive/alimentary system

increased intestinal iron level ( J:129846 )

• significant iron accumulation in duodenal enterocytes at P12

immune system

increased spleen iron level ( J:129846 )

• significant iron accumulation in splenic macrophages at P12

• at P18 - P22 spleen iron are increased 4.4-fold increase compared to controls

liver/biliary system

abnormal liver iron level ( J:129846 )

• significant iron accumulation in the Kupffer cells and hepatocytes at P12

• at P18 - P22 iron levels in the liver are reduced by 1.7-fold compared to controls

integument

pallor ( J:129846 )

• apparent within a few days of birth

• difference from controls becomes more prominent with age

Allelic Composition	Slc40a1^tm2Nca/Slc40a1^tm2Nca Tg(Vil1-cre)20Syr/0
Genetic Background	involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc40a1^tm2Nca mutation (1 available); any Slc40a1 mutation (53 available)
Tg(Vil1-cre)20Syr mutation (3 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

prenatal lethality, complete penetrance ( J:129846 )

• no mice are found at birth due to recombination in the extraembryonic visceral endoderm

Allelic Composition	Slc40a1^tm2Nca/Slc40a1^tm2Nca Tg(Vil1-cre/ERT2)23Syr/0
Genetic Background	involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc40a1^tm2Nca mutation (1 available); any Slc40a1 mutation (53 available)
Tg(Vil1-cre/ERT2)23Syr mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

anemia ( J:129846 )

• visibly anemic by 8 days after the first tamoxifen injection

• severe iron deficient anemia develops by 6 - 7 weeks after the start of tamoxifen treatment

decreased hematocrit ( J:129846 )

• by 6 - 7 weeks after the start of tamoxifen treatment, average hematocrit is 11.2 +/- 1.6% compared to 45.3 +/- 5.9% in controls without the cre transgene

• parenteral treatment with iron dextran restores hematocrits in tamoxifen treated mice to levels similar to control mice that do not carry the cre transgene

decreased hemoglobin content ( J:129846 )

• by 6 - 7 weeks after the start of tamoxifen treatment, average hemoglobin concentration is 2.8 +/- 0.6 g/dl compared to 13.8 +/- 1.8 g/dl in controls without the cre transgene

decreased spleen iron level ( J:129846 )

• a 4.7-fold decrease in splenic nonheme iron is seen after tamoxifen treatment

homeostasis/metabolism

increased intestinal iron level ( J:129846 )

• significant iron accumulation in duodenal enterocytes after tamoxifen treatment

decreased spleen iron level ( J:129846 )

• a 4.7-fold decrease in splenic nonheme iron is seen after tamoxifen treatment

decreased liver iron level ( J:129846 )

• a 5.5-fold decrease in hepatic nonheme iron is seen after tamoxifen treatment

digestive/alimentary system

increased intestinal iron level ( J:129846 )

• significant iron accumulation in duodenal enterocytes after tamoxifen treatment

immune system

decreased spleen iron level ( J:129846 )

• a 4.7-fold decrease in splenic nonheme iron is seen after tamoxifen treatment

liver/biliary system

decreased liver iron level ( J:129846 )

• a 5.5-fold decrease in hepatic nonheme iron is seen after tamoxifen treatment

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/30/2024 MGI 6.23